KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Thermo Fisher Scientific (TMO) Change in Account Payables (2016 - 2020)

Thermo Fisher Scientific filings provide 12 years of Change in Account Payables readings, the most recent being $279.0 million for Q4 2020.

  • On a quarterly basis, Change in Account Payables rose 42.35% to $279.0 million in Q4 2020 year-over-year; TTM through Dec 2020 was $59.0 million, a 77.82% decrease, with the full-year FY2025 number at $421.0 million, up 98.58% from a year prior.
  • Change in Account Payables hit $279.0 million in Q4 2020 for Thermo Fisher Scientific, up from $277.0 million in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $279.0 million in Q4 2020 to a low of -$256.0 million in Q2 2020.
  • Median Change in Account Payables over the past 5 years was $15.6 million (2016), compared with a mean of $42.8 million.
  • The widest YoY moves for Change in Account Payables: up 2812.87% in 2017, down 1374.51% in 2017.
  • Thermo Fisher Scientific's Change in Account Payables stood at -$10.1 million in 2016, then surged by 2812.87% to $274.0 million in 2017, then decreased by 10.22% to $246.0 million in 2018, then decreased by 20.33% to $196.0 million in 2019, then soared by 42.35% to $279.0 million in 2020.
  • The last three reported values for Change in Account Payables were $279.0 million (Q4 2020), $277.0 million (Q3 2020), and -$256.0 million (Q2 2020) per Business Quant data.